Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Illumina (ILMN), a provider of genetic and genomic analysis solutions, is highlighted by Zacks as a top momentum stock, despite its #3 (Hold) Zacks Rank, due to its B Momentum and VGM Style Scores. The company's shares have gained 5.6% over the past four weeks, underpinned by seven analyst upgrades to fiscal 2025 earnings estimates, which raised the consensus to $4.42 per share, and a historical average earnings surprise of +10.6%. This combination of strong momentum and positive analyst sentiment positions ILMN as a notable consideration for investors.

Analysis

Illumina (ILMN) exhibits a profile of strengthening positive momentum and improving analyst sentiment, despite its neutral Zacks #3 (Hold) rating. The stock has gained 5.6% over the past four weeks, a trend supported by its 'B' grade for Momentum Style Score. More significantly, the forward-looking earnings outlook has brightened, with seven analysts revising their fiscal 2025 earnings estimates upward in the last 60 days. This has resulted in a $0.18 increase in the Zacks Consensus Estimate to $4.42 per share for fiscal 2025. The company's history of exceeding market expectations, evidenced by an average positive earnings surprise of 10.6%, provides additional support for the bullish momentum thesis. According to the provided framework, the combination of a 'B' grade for its overall VGM Style Score with the neutral rank suggests potential for upside that warrants investor attention.

Key Decisions for Investors

• Given the positive price momentum and upward earnings estimate revisions for fiscal 2025, investors with a focus on momentum strategies may find ILMN to be a compelling stock to watch or add to.
• The neutral Zacks #3 (Hold) rank should be considered a moderating factor, suggesting that while near-term indicators are positive, a fully bullish conviction may require further fundamental confirmation beyond the scope of this report.
• Investors should closely monitor the trend in analyst earnings estimates for FY2025, as the current positive thesis is heavily reliant on the continuation of these upward revisions.